Publication:
Immunostimulatory CpG oligodeoxynucleotide confers protection in a murine model of infection with Burkholderia pseudomallei

dc.contributor.authorSurasakdi Wongratanacheewinen_US
dc.contributor.authorWannapa Kespichayawattanaen_US
dc.contributor.authorPakamas Intachoteen_US
dc.contributor.authorSathit Pichyangkulen_US
dc.contributor.authorRasana W. Sermswanen_US
dc.contributor.authorArthur M. Kriegen_US
dc.contributor.authorStitaya Sirisinhaen_US
dc.contributor.otherKhon Kaen Universityen_US
dc.contributor.otherChulabhorn Research Instituteen_US
dc.contributor.otherArmed Forces Research Institute of Medical Sciences, Thailanden_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherPfizer Inc.en_US
dc.date.accessioned2018-07-24T03:43:10Z
dc.date.available2018-07-24T03:43:10Z
dc.date.issued2004-08-01en_US
dc.description.abstractAlthough CpG oligodeoxynucleotides (CpG ODNs) are known to enhance resistance against infection in a number of animal models, little is known about the CpG-induced protection against acute fatal sepsis such as that associated with the highly virulent bacterium Burkholderia pseudomallei. We previously demonstrated in an in vitro study that immunostimulatory CpG ODN 1826 enhances phagocytosis of B. pseudomallei and induces nitric oxide synthase and nitric oxide production by mouse macrophages. In the present study, CpG ODN 1826 given intramuscularly to BALB/c mice 2 to 10 days prior to B. pseudomallei challenge conferred better than 90% protection. CpG ODN 1826 given 2 days before the bacterial challenge rapidly enhanced the innate immunity of these animals, judging from the elevated serum levels of interleukin-12 (IL-12)p70 and gamma interferon (IFN-γ) over the baseline values. No bacteremia was detected on day 2 in 85 to 90% of the CpG-treated animals, whereas more than 80% of the untreated animals exhibited heavy bacterial loads. Although marked elevation of IFN-γ was found consistently in the infected animals 2 days after the bacterial challenge, it was ameliorated by the CpG ODN 1826 pretreatment (P = 0.0002). Taken together, the kinetics of bacteremia and cytokine profiles presented are compatible with the possibility that protection by CpG ODN 1826 against acute fatal septicemic melioidosis in this animal model is associated with a reduction of bacterial load and interference with the potential detrimental effect of the robust production of proinflammatory cytokines associated with B. pseudomallei multiplication.en_US
dc.identifier.citationInfection and Immunity. Vol.72, No.8 (2004), 4494-4502en_US
dc.identifier.doi10.1128/IAI.72.8.4494-4502.2004en_US
dc.identifier.issn00199567en_US
dc.identifier.other2-s2.0-3342894608en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/21367
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=3342894608&origin=inwarden_US
dc.subjectImmunology and Microbiologyen_US
dc.subjectMedicineen_US
dc.titleImmunostimulatory CpG oligodeoxynucleotide confers protection in a murine model of infection with Burkholderia pseudomalleien_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=3342894608&origin=inwarden_US

Files

Collections